proprietary products target a clearly-defined pathway, the Urokinase Plasminogen Activation System (PA), which has repeatedly been shown in scientific literature to be directly involved in proliferative diseases, such as cancer and wet age-related macular degeneration (ARMD).
Member count: 11-50
Investors 1
| Date | Name | Website |
| - | Solstice C... | solcap.com |